LumaGEM MBI for Adjunct Screening
Breast Cancer Detection in Dense Breast Tissue
CommercialActive
Key Facts
Indication
Breast Cancer Detection in Dense Breast Tissue
Phase
Commercial
Status
Active
Company
About CMR Naviscan
CMR Naviscan, a unit of the larger CMR corporation, is a commercial-stage medical device company specializing in molecular breast imaging. Its core product, the LumaGEM MBI system, addresses a critical gap in breast cancer screening for the approximately 40-50% of women with dense breast tissue, where mammography is less effective. The company's value proposition is built on clinical data showing increased invasive cancer detection rates and a reduction in unnecessary biopsies, leading to proven healthcare savings. Operating as a private entity, it leverages over 40 years of parent company expertise in diagnostic imaging to market its FDA-registered systems.
View full company profile